RxDoctor Payments Data

Mohan Jacob, MD

Cardiovascular Disease · Humble, TXNPI 1942267448

Payments from drug & device makers

$1,185in general payments, 2019–2025

Across 19 payments — averaging $62.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$576
  • Abbott$438
  • Johnson & Johnson$68
  • Amarin Pharma, Inc.$27
  • Pfizer$25
  • Merck$22
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$1,16398%
  • Education$222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,185 in reported general payments places this provider in the 25th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$301,500
Medicare patients
176
Services billed
1,964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban168$219,974
XareltoRivaroxaban33$48,296
BrilintaTicagrelor12$13,963
EntrestoSacubitril/Valsartan12$10,588
Metoprolol Succinate415$9,821
Nifedipine ErNifedipine122$3,327
Levothyroxine Sodium225$2,765
Atorvastatin Calcium293$2,614
Rosuvastatin Calcium119$2,595
Valsartan52$2,023
Lisinopril219$1,972
Amlodipine Besylate226$1,958
Potassium Chloride69$1,917
Ezetimibe81$1,625
ClopidogrelClopidogrel Bisulfate107$1,597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Levoxyl$25$220,371182 claims
Johnson & JohnsonXarelto$68$48,29633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Humble

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →